Lymphogranuloma venereum laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Because of limitations in a commercially available test, diagnosis is primarily based on clinical findings. Direct identification of the bacteria from a lesion or site of the infection may be possible through testing for [[chlamydia]] but, this would not indicate if the chlamydia infection is LGV. However, the usual chlamydia tests that are available have not been FDA approved for testing rectal specimens. In a patient with rectal signs or symptoms suspicious for LGV, a health care provider can collect a specimen and send the sample to his/her state health department for referral to CDC, which is working with state and local health departments to test specimens and validate diagnostic methods for LGV.
Because of limitations in commercially available tests, clinical presentation, in conjunction to laboratory findings, plays an important role in diagnosis. ''C. trachomatis'' can be identified from lesion swabs, [[bubo]] aspirate, or [[rectal]] [[mucosa]] swabs (in patients with [[proctitis]]) using culture methods, [[Serology|serologic]] testing, and nucleic acid amplification tests (NAATs). Culture is impractical since it is time consuming and lacks sensitivity. Compliment fixation and immunofluorescence serologic tests are sensitive but only genus specific. NAATs are the most reliable method for detecting ''C. trachomatis'' and real-time [[Polymerase Chain Reaction|PCR]] can detect the LGV-specific [[serovar]].


==Laboratory Findings==
==Laboratory Findings==

Revision as of 16:41, 25 February 2016

Lymphogranuloma venereum Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Classification

Differentiating Lymphogranuloma venereum from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lymphogranuloma venereum laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphogranuloma venereum laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphogranuloma venereum laboratory findings

CDC on Lymphogranuloma venereum laboratory findings

Lymphogranuloma venereum laboratory findings in the news

Blogs on Lymphogranuloma venereum laboratory findings

Directions to Hospitals Treating Lymphogranuloma venereum

Risk calculators and risk factors for Lymphogranuloma venereum laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nate Michalak, B.A.

Overview

Because of limitations in commercially available tests, clinical presentation, in conjunction to laboratory findings, plays an important role in diagnosis. C. trachomatis can be identified from lesion swabs, bubo aspirate, or rectal mucosa swabs (in patients with proctitis) using culture methods, serologic testing, and nucleic acid amplification tests (NAATs). Culture is impractical since it is time consuming and lacks sensitivity. Compliment fixation and immunofluorescence serologic tests are sensitive but only genus specific. NAATs are the most reliable method for detecting C. trachomatis and real-time PCR can detect the LGV-specific serovar.

Laboratory Findings

Culture

  • Primary lesion swabs or bubo aspirate can be cultured on cyclohexamide-treated McCoy or HeLa cells.
  • Sensitivity is approximately 75% - 85%.[1]
  • Culture is impractical due to its time-consuming nature, the fact that it's not readily available, and the test yields isolate only 30% of the time.[2]

Serology

  • Compliment fixation and immunofluorescence tests of lesion swab or bubo aspirate can be used to detect C. trachomatis.
  • Serology is only genus specific.
  • Cross-reactivity with other species is possible.[2]
  • A complement fixation titer of >1:64 with appropriate clinical presentation is suggestive of LGV.
  • An immunofluorescence titer of >1:256 with appropriate clinical presentation is suggestive of LGV.[3]

Nucleic Acid Amplification Tests (NAATs)

  • Lesion swabs, bubo aspirate, or rectal mucosa swabs can be tested for C. trachomatis using nucleic acid amplification tests (NAATs).
  • NAATs have high specificity and sensitivity for C. trachomatis.[1]
  • NAATs performed on rectal specimens are not approved by the FDA but appear more accurate than other testing methods and are the preferred approach.[3]
  • A biovar-specific polymerase chain reaction (PCR) test has been developed to detect the L-type serovars of LGV C. trachomatis.[1]

References

  1. 1.0 1.1 1.2 Ceovic R, Gulin SJ (2015). "Lymphogranuloma venereum: diagnostic and treatment challenges". Infect Drug Resist. 8: 39–47. doi:10.2147/IDR.S57540. PMC 4381887. PMID 25870512.
  2. 2.0 2.1 Mabey, D (2002). "Lymphogranuloma venereum". Sexually Transmitted Infections. 78 (2): 90–92. doi:10.1136/sti.78.2.90. ISSN 1368-4973.
  3. 3.0 3.1 2015 Sexually Transmitted Diseases Treatment Guidelines. Centers for Disease Control and Prevention (June 4, 2015). http://www.cdc.gov/std/tg2015/lgv.htm Accessed February 25, 2016.

Template:WikiDoc Sources